share_log

10-K/A: Annual report (Amendment)

10-K/A: Annual report (Amendment)

10-K/A:年度報表(修正版)
美股sec公告 ·  04/29 16:21
Moomoo AI 已提取核心訊息
180 Life Sciences Corp. (180 Life Sciences) has filed an amended annual report for the fiscal year ended December 31, 2023. The report includes the dismissal of Marcum LLP as the independent registered public accounting firm and the engagement of M&K CPA’s, PLLC for the fiscal year 2024. The company has also entered into indemnification agreements with directors and officers, and has established a policy for the Audit Committee to review and approve any related party transactions. Legal actions involving former CEO Dr. Marlene Krauss and Tyche Capital LLC are ongoing, with the company vigorously defending its position. The company has also initiated legal action against Ronald Bauer and Samantha Bauer for misappropriated funds and stock shares. The Board has determined that new appointees Blair Jordan, Omar Jiminez, and Ryan Smith are independent directors. The report also details the compensation of directors and executive officers, including equity compensation plans and related fees for services rendered during the fiscal year.
180 Life Sciences Corp. (180 Life Sciences) has filed an amended annual report for the fiscal year ended December 31, 2023. The report includes the dismissal of Marcum LLP as the independent registered public accounting firm and the engagement of M&K CPA’s, PLLC for the fiscal year 2024. The company has also entered into indemnification agreements with directors and officers, and has established a policy for the Audit Committee to review and approve any related party transactions. Legal actions involving former CEO Dr. Marlene Krauss and Tyche Capital LLC are ongoing, with the company vigorously defending its position. The company has also initiated legal action against Ronald Bauer and Samantha Bauer for misappropriated funds and stock shares. The Board has determined that new appointees Blair Jordan, Omar Jiminez, and Ryan Smith are independent directors. The report also details the compensation of directors and executive officers, including equity compensation plans and related fees for services rendered during the fiscal year.
180 生命科學公司(180 Life Sciences)已提交了截至2023年12月31日的財年的修訂年度報告。該報告包括解除Marcum LLP作爲獨立註冊會計師事務所的職務,以及M&K CPA,PLLC在2024財年的聘用。該公司還與董事和高級管理人員簽訂了賠償協議,並制定了一項政策,供審計委員會審查和批准任何關聯方交易。涉及前首席執行官瑪琳·克勞斯博士和泰馳資本有限責任公司的法律訴訟正在進行中,該公司正在大力捍衛自己的立場。該公司還以挪用資金和股票爲由對羅納德·鮑爾和薩曼莎·鮑爾提起法律訴訟。董事會已確定新任命的布萊爾·喬丹、奧馬爾·吉米內斯和瑞安·史密斯爲獨立董事。該報告還詳細介紹了董事和執行官的薪酬,包括股權薪酬計劃和本財年提供服務的相關費用。
180 生命科學公司(180 Life Sciences)已提交了截至2023年12月31日的財年的修訂年度報告。該報告包括解除Marcum LLP作爲獨立註冊會計師事務所的職務,以及M&K CPA,PLLC在2024財年的聘用。該公司還與董事和高級管理人員簽訂了賠償協議,並制定了一項政策,供審計委員會審查和批准任何關聯方交易。涉及前首席執行官瑪琳·克勞斯博士和泰馳資本有限責任公司的法律訴訟正在進行中,該公司正在大力捍衛自己的立場。該公司還以挪用資金和股票爲由對羅納德·鮑爾和薩曼莎·鮑爾提起法律訴訟。董事會已確定新任命的布萊爾·喬丹、奧馬爾·吉米內斯和瑞安·史密斯爲獨立董事。該報告還詳細介紹了董事和執行官的薪酬,包括股權薪酬計劃和本財年提供服務的相關費用。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息